Journal
NEUROBIOLOGY OF AGING
Volume 32, Issue 12, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2010.05.004
Keywords
Oligomeric A beta; Cognitive function; Spatial memory; Basal neuronal transmission; Dendritic spine; Synaptic plasticity; Bioavailability
Categories
Funding
- NIH [UO1 AG29310]
- Altschul Foundation
- Grants-in-Aid for Scientific Research [22790815] Funding Source: KAKEN
Ask authors/readers for more resources
Oligomeric beta-amyloid (A beta) has recently been linked to synaptic plasticity deficits, which play a major role in progressive cognitive decline in Alzheimer's disease (AD). Here we present evidence that chronic oral administration of carvedilol, a nonselective beta-adrenergic receptor blocker, significantly attenuates brain oligomeric beta-amyloid content and cognitive deterioration in 2 independent AD mouse models. We found that carvedilol treatment significantly improved neuronal transmission, and that this improvement was associated with the maintenance of number of the less stable learning thin spines in the brains of AD mice. Our novel observation that carvedilol interferes with the neuropathologic, biochemical, and electrophysiological mechanisms underlying cognitive deterioration in AD supports the potential development of carvedilol as a treatment for AD. (C) 2011 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available